|Chemical and physical data|
|Molar mass||391.46 g/mol|
|3D model (JSmol)|
Flavoxate is used to treat urinary bladder spasms. It is available under the trade name Urispas (Paladin), Genurin (by Recordati, Italy) in Italy and KSA, Uritac by El Saad company in Syria, under the name Bladderon by Nippon Shinyaku of Japan, or Bladuril in Chile, Utispas ( Apex Pharma) in Nepal.
Flavoxate is indicated for symptomatic relief of interstitial cystitis, dysuria, urgency, nocturia, suprapubic pain, frequency and incontinence as may occur in cystitis, prostatitis, urethritis, urethrocystitis/urethrotrigonitis.
Flavoxate is contraindicated in patients who have any of the following obstructive conditions: pyloric or duodenal obstruction, obstructive intestinal lesions or ileus, achalasia, gastrointestinal hemorrhage and obstructive uropathies of the lower urinary tract.
- Zakir SM, Zaka-ur-Rab S, Salman MT, Khan RA. Bilateral acute angle closure glaucoma in a 50-year-old female after oral administration of flavoxate. British Journal of Clinical Pharmacology. 2008. 66(5):726-727
- Brenner, G. M. (2000). Pharmacology. Philadelphia, PA: W.B. Saunders Company. ISBN 0-7216-7757-6
- Canadian Pharmacists Association (2000). Compendium of Pharmaceuticals and Specialties (25th ed.). Toronto, ON: Webcom. ISBN 0-919115-76-4
- U.S. National Library of Medicine, National Institutes of Health. "Flavoxate". PubMed Health. https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0000753